Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,012 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Influenza Virus Clear all

Conditions: Influenza
Interventions: Fluzone® (intramuscular), FluMist® (intranasal); Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 100 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia, Influenza, Human, ARDS, Human
Interventions: AlloStim; Drug
Lead sponsor: Mirror Biologics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Delray Beach, Florida • Miami, Florida • Tampa, Florida + 1 more

Conditions: Influenza
Interventions: Not listed
Lead sponsor: QIAGEN Gaithersburg, Inc; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Tucson, Arizona • Chapel Hill, North Carolina • Columbus, Ohio

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions: Aptitude Medical Systems Metrix COVID/Flu Test; Diagnostic Test
Lead sponsor: Aptitude Medical Systems; Industry
Eligibility: 2 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts

Conditions: Influenza
Interventions: Oseltamivir, MEDI8852, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Canoga Park, California • Long Beach, California • Los Angeles, California + 15 more

Conditions: Influenza
Interventions: Influenza vaccine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 4,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pregnancy
Interventions: Text message surveillance; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Avian Influenza
Interventions: ND1.1; Biological
Lead sponsor: Vaxart; Industry
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Influenza
Interventions: Blood Draw; Procedure
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Smoking
Interventions: Broccoli sprout homogenate, Alfalfa sprout homogenate; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 40 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Influenza
Interventions: Fluzone Quadrivalent vaccine, 2016-2017 formulation, No Preservative, Fluzone High-Dose, vaccine, 2016-2017 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years and older
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Bardstown, Kentucky • Metairie, Louisiana

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 817 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Conditions: Influenza Viral Infections
Interventions: Influenza A/Texas/71/2017 (H3N2), Sham placebo; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 46 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: H1N1 Influenza Virus
Interventions: H1N1 vaccine high dose, H1N1 vaccine low dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more

Conditions: Smoke Exposure, Influenza
Interventions: LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure); Biological · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 49 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Influenza Infection
Interventions: VAX102 [Flagellin.HuM2e], Placebo; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Lenexa, Kansas • Galveston, Texas

Conditions: Influenza
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: VIS410, Placebo; Drug
Lead sponsor: Visterra, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Influenza, Human, Influenza, Flu
Interventions: Diassess Influenza A and B Test; Device
Lead sponsor: Diassess Inc.; Industry
Eligibility: Not listed
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Influenza
Interventions: CAIV-T, TIV; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Layton, Utah • Ogden, Utah • Pleasant Grove, Utah + 2 more

Conditions: Influenza, Human
Interventions: mIRV, bIRV AB, qIRV, QIV, bIRV AA, bIRV BB; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 100
States / cities: Athens, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Influenza, Human
Interventions: Seasonal LAIV, Placebo, Wild-type A/California/2009-like Influenza Virus; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Universal Anti-Viral Vaccine for Healthy Elderly Adults

Collection and Extraction of Respiratory Specimens

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza

Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season

Influenza Resistance Information Study

PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging

Immunogenicity of ND1.1 by Delivery Directly to the Ileum

Immunogenicity of Influenza Vaccine in Long Term Care

Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Single Dose Texas 2017 (H3N2) Challenge Study

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

Clinical Characteristics and Outcomes in Patients Diagnosed With Novel Influenza A (H1N1)

A Study of VIS410 to Assess Safety and Pharmacokinetics

Clinical Performance of the Diassess Influenza A and B Test

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus